XLO FY 2022 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

XLOXilio Therapeutics, Inc.

$28M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$89M

Net Income

-$88M

EPS (Diluted)

$-3.19

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$78M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$139M

Total Liabilities

$34M

Stockholders' Equity

$106M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$1M	+100.0%
Operating Income	-$89M	-$75M	-18.8%
Net Income	-$88M	-$76M	-16.4%